FDA Staff Cuts and Drug Approval Delays: A Potential Link
The article discusses potential delays in drug approvals by the FDA. Stealth BioTherapeutics reports the FDA missed a deadline for a rare disease drug, elamipretide. The article implies a possible connection between staff reductions at the FDA and the slowing of the drug approval process. It highlights the impact these delays could have on patients awaiting treatment for rare conditions.